Drugs

, Volume 62, Supplement 1, pp 33–46 | Cite as

Treatment of Aggressive Non-Hodgkin’s Lymphoma with Chemotherapy in Combination with Filgrastim

Review Article

Abstract

Non-Hodgkin’s lymphoma (NHL) is one of the ten most common cancers in the developed world. The incidence has increased significantly over the past two decades and it is a particular burden in patients over the age of 60 years. The gold standard for primary treatment of aggressive NHL is combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Haematological growth factors, such as granulocyte colony-stimulating factor (G-CSF), can be used to ameliorate chemotherapy-induced neutropenia, thus facilitating delivery of chemotherapy at the planned dose intensity. The International Prognostic Index is able to identify high-risk patients who are unlikely to be cured with standard primary chemotherapy. In these patients, the use of dose-intensive therapy, including high-dose chemotherapy with stem cell support, is being evaluated as potential primary therapy. Stem cell transplantation is currently the treatment of choice for patients with relapsed NHL or those with chemosensitive refractory disease. Autologous peripheral blood stem cells mobilised into the circulation by G-CSF help achieve rapid haematological reconstitution and are now the preferred source of stem cells over bone marrow for this form of therapy. G-CSF is also used to support allogeneic transplantation, which exerts a therapeutic graft-versus-lymphoma effect. Administration of G-CSF following autologous or allogeneic peripheral blood stem cell transplantation accelerates neutrophil recovery.

References

  1. 1.
    Koc Y, Schenkein DP. Therapy of diffuse aggressive lymphoma. Cancer Treat Res 1999; 99: 47–73PubMedCrossRefGoogle Scholar
  2. 2.
    Wingo PA, Ries LA, Rosenberg HM, et al. Cancer incidence and mortality, 1973–1995: a report card for the US. Cancer 1998; 82: 1197–207PubMedCrossRefGoogle Scholar
  3. 3.
    Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–92PubMedGoogle Scholar
  4. 4.
    The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. Blood 1997; 89: 3909–18Google Scholar
  5. 5.
    Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419–32PubMedCrossRefGoogle Scholar
  6. 6.
    Shipp MA. A predictive model for aggressive non-Hodgkin’s lymphoma. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–94CrossRefGoogle Scholar
  7. 7.
    Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med 1993; 328: 1002–6PubMedCrossRefGoogle Scholar
  8. 8.
    Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–76PubMedGoogle Scholar
  9. 9.
    Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–42PubMedCrossRefGoogle Scholar
  10. 10.
    Cheson BD. CHOP plus rituximab — balancing facts and opinion. N Engl J Med 2002; 346: 280–2PubMedCrossRefGoogle Scholar
  11. 11.
    Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin’s lymphoma: a randomized controlled trial. Blood 1992; 80: 1430–6PubMedGoogle Scholar
  12. 12.
    Gisselbrecht C, Haioun C, Lepage E, et al. Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin’s lymphoma: factors influencing chemotherapy administration. Groupe d’Etude des Lymphomes de l’Adulte. Leuk Lymphoma 1997; 25: 289–300PubMedGoogle Scholar
  13. 13.
    Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin’s lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94: 33–8PubMedGoogle Scholar
  14. 14.
    Donnelly GB, Glassman J, Long C, et al. Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy. Leuk Lymphoma 2000; 39: 67–75PubMedCrossRefGoogle Scholar
  15. 15.
    Itoh K, Ohtsu T, Wakita H, et al. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin’s lymphoma. Ann Oncol 2000; 11: 1241–7PubMedCrossRefGoogle Scholar
  16. 16.
    Tanosaki R, Okamoto S, Akatsuka N, et al. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin’s lymphoma. Cancer 1994; 74: 1939–44PubMedCrossRefGoogle Scholar
  17. 17.
    Santoro A, Balzarotti M, Tondini C, et al. Dose-escalation of CHOP in non-Hodgkin’s lymphoma. Ann Oncol 1999; 10: 519–25PubMedCrossRefGoogle Scholar
  18. 18.
    Pfreundschuh M, Trumper L, Kloess M, et al. 2-weekly chop (CHOP-14): the new standard regimen for patients with aggressive non-Hodgkin’s lymphoma (NHL) >60 years of age [abstract #3027]. American Society of Hematology; 2001 Dec 7–11; Orlando (FL)Google Scholar
  19. 19.
    Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353–7PubMedCrossRefGoogle Scholar
  20. 20.
    Hartmann O, Le Corroller AG, Blaise D, et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs: a randomized, controlled trial. Ann Intern Med 1997; 126: 600–7PubMedGoogle Scholar
  21. 21.
    Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995; 85: 1655–8PubMedGoogle Scholar
  22. 22.
    Schmitz N, Dreger P, Zander AR, et al. Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stimulating factor (filgrastim) in patients with Hodgkin’s disease and non-Hodgkin’s lymphoma undergoing autologous bone marrow transplantation. Bone Marrow Transplant 1995; 15: 261–6PubMedGoogle Scholar
  23. 23.
    Linch DC, Milligan DW, Winfield DA, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. Br J Haematol 1997; 99: 933–8PubMedCrossRefGoogle Scholar
  24. 24.
    Bishop MR, Tarantolo SR, Geller RB, et al. A randomized, double-blind trial of filgrastim (granulocyte colony-stimulating factor) versus placebo following allogeneic blood stem cell transplantation. Blood 2000; 96: 80–5PubMedGoogle Scholar
  25. 25.
    Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963–77PubMedGoogle Scholar
  26. 26.
    Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin’s lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d’Etude des Lymphomes de l’Adulte). Ann Oncol 1993; 4: 651–6PubMedGoogle Scholar
  27. 27.
    Zelenetz AD, Reider PA, Delgado DJ. Review of patterns of care among community physicians in intermediate grade NHL (IGL) reveals significantly greater planned and delivered dose attenuation in older patients [abstract #588] American Society of Hematology; 2000 Dec 1–5; San Francisco (CA)Google Scholar
  28. 28.
    Balducci L, Yates J. General guidelines for the management of older patients with cancer. Oncology (Huntingt) 2000; 14: 221–7Google Scholar
  29. 29.
    Shipp MA, Abeloff MD, Antman KH, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin’s Lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–9PubMedGoogle Scholar
  30. 30.
    Hahn T, Wolff SN, Czuczman MS, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2001; 7: 308–31PubMedCrossRefGoogle Scholar
  31. 31.
    Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–7PubMedCrossRefGoogle Scholar
  32. 32.
    Milpied N, Deconninck E, Colombat P, et al. A GOELAMS trial. Frontline high-dose chemotherapy (HDC) with autologous stem cell transplantation compared to standard CHOP regimen: a randomized trial for adult patients with non IPI high-risk intermediate or high grade lymphomas (NHL) [abstract]. Blood 1999; 94: 610aGoogle Scholar
  33. 33.
    Kewalramani T, Zelenetz AD, Hedrick EE, et al. High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 2000; 96: 2399–404PubMedGoogle Scholar
  34. 34.
    Vose JM, Zhang MJ, Rowlings PA, et al. Autologous transplantation for diffuse aggressive non-Hodgkin’s lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–13PubMedGoogle Scholar
  35. 35.
    Verdonck LF, van Putten WL, Hagenbeek A, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 1995; 332: 1045–51PubMedCrossRefGoogle Scholar
  36. 36.
    Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphoma: results of a prospective randomized trial by the non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796–802PubMedGoogle Scholar
  37. 37.
    Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol — a Groupe d’Etude des Lymphomes de l’Adulte study. J Clin Oncol 2000; 18: 3025–30PubMedGoogle Scholar
  38. 38.
    Bouabdallah R, Coso D, Costello R, et al. Role of high-dose therapy and initial response in survival of poor-risk patients with aggressive non-Hodgkin’s lymphoma: a retrospective series on 126 patients from a single center. Bone Marrow Transplant 2000; 25: 35–40PubMedCrossRefGoogle Scholar
  39. 39.
    NCCN preliminary non-Hodgkin’s lymphoma practice guidelines. Oncology (Huntingt) 1997; 11: 281–46Google Scholar
  40. 40.
    Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol 1999; 17: 3776–85PubMedGoogle Scholar
  41. 41.
    Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–22PubMedGoogle Scholar
  42. 42.
    Philip T, Gugliemi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995; 333: 1540–5PubMedCrossRefGoogle Scholar
  43. 43.
    Jones RJ, Ambinder RF, Piantadosi S, et al. Evidence of agraftversus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–53PubMedGoogle Scholar
  44. 44.
    Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin’s lymphoma. Blood 1994; 84: 1050–5PubMedGoogle Scholar
  45. 45.
    van Besien K, Thall P, Korbling M, et al. Allogeneic transplantation for recurrent or refractory non-Hodgkin’s lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: experience in 44 consecutive patients. Biol Blood Marrow Transplant 1997; 3: 150–6PubMedGoogle Scholar
  46. 46.
    Lundberg JH, Hansen RM, Chitambar CR, et al. Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. J Clin Oncol 1991; 9: 1848–59PubMedGoogle Scholar
  47. 47.
    Dann EJ, Daugherty CK, Larson RA. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin’s disease and non-Hodgkin’s lymphoma. Bone Marrow Transplant 1997; 20: 369–74PubMedCrossRefGoogle Scholar
  48. 48.
    Dhedin N, Giraudier S, Gaulard P, et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin’s lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societe Francaise de Greffe de Moelle. Br J Haematol 1999; 107: 154–61PubMedCrossRefGoogle Scholar
  49. 49.
    Khouri IF, Keating M, Korbling M. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–24PubMedGoogle Scholar
  50. 50.
    Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–63PubMedGoogle Scholar
  51. 51.
    Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631–7PubMedCrossRefGoogle Scholar
  52. 52.
    Carella AM, Cavaliere M, Lerma E, et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin’s disease and non-Hodgkin’s lymphoma. J Clin Oncol 2000; 18: 3918–24PubMedGoogle Scholar
  53. 53.
    Gratwohl A, Passweg J, Baldomero H, et al. Blood and marrow transplantation activity in Europe 1997. European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999; 24: 231–45PubMedCrossRefGoogle Scholar
  54. 54.
    Weaver C, Schulman K, Buckner C. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant 2001; 27 Suppl. 2: S23–9PubMedCrossRefGoogle Scholar
  55. 55.
    Stiff P, Gingrich R, Luger S, et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin’s disease or non-Hodgkin’s lymphoma. Bone Marrow Transplant 2000; 26: 471–81PubMedCrossRefGoogle Scholar
  56. 56.
    Bishop MR, Tarantolo SR, Jackson JD, et al. Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor. J Clin Oncol 1997; 15: 1601–7PubMedGoogle Scholar
  57. 57.
    Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–81PubMedCrossRefGoogle Scholar
  58. 58.
    Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 1231–7PubMedCrossRefGoogle Scholar
  59. 59.
    Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000; 95: 3702–9PubMedGoogle Scholar
  60. 60.
    Morton J, Hutchins C, Durrant S. Granulocyte-colony-stimulating factor (G-CSF)-primed allogeneic bone marrow: significantly less graft-versus-host disease and comparable engraftment to G-CSF-mobilized peripheral blood stem cells. Blood 2001; 98: 3186–91PubMedCrossRefGoogle Scholar
  61. 61.
    Rowley SD, Donaldson G, Lilleby K, et al. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001; 97: 2541–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.City of Hope Samaritan BMT UnitPhoenixUSA

Personalised recommendations